Scotiabank analyst Greg Harrison lowered the firm’s price target on Vera Therapeutics (VERA) to $55 from $60 and keeps an Outperform rating on the shares. The firm is updating its price targets ...

Analyst Greg Harrison lowered his rating to Sector Perform from Sector Outperform and slashed his price target on GERN to $1.50 from $4.00 per share, noting that the downgrade was not only due to ...